AFFIMED NV (AFMD)
NL0015001ZQ0 - Common Stock
AFMD Stock Earnings: Affimed Beats EPS, Misses Revenue for Q4 2023
AFMD stock results show that Affimed beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2023.
AFMD Stock Earnings: Affimed Beats EPS, Misses Revenue for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Affimed (NASDAQ:AFMD) just reported results for the fourth quarter of 2023.Affi...
Affimed Reports 2023 Financial Results and Operational Progress
Affimed Reports 2023 Financial Results and Operational Progress
AFM24 combination with atezolizumab (AFM24-102): Follow-up of the Phase 1/2a combination study confirmed four responses in the non-small cell cancer...
Affimed To Report Full Year 2023 Financial Results & Corporate Update on March 28, 2024
Affimed To Report Full Year 2023 Financial Results & Corporate Update on March 28, 2024
MANNHEIM, Germany, March 21, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company...
ASTR Stock Alert: Astra Space Is Going Private
Astra Space stock is in the news Friday as ASTR investors react to news that the company is being taken private in Q2 2024.
Why Is AerSale (ASLE) Stock Down 18% Today?
AerSale stock is down on Friday as investors in ASLE react to misses in the aftermarket commercial aircraft seller's Q4 2024 earnings report.
Why Is Affimed (AFMD) Stock Moving Today?
Affimed stock is on the move Friday as investors prepare for AFMD shares to undergo a one-for-10 reverse split later today.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
We're starting the final day of trading this week with a breakdown of the biggest pre-market stock movers for Friday morning!
7 of the Best Speculative Stocks You Can Snag for Less Than $1
Although speculative stocks under $1 are by their very nature extremely risky, these ideas might have enough to go the distance.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
We're starting Wednesday with a breakdown of the biggest pre-market stock movers traders will want to keep an eye on this morning!
Affimed Announces 1-for-10 Reverse Stock Split
Affimed Announces 1-for-10 Reverse Stock Split
MANNHEIM, Germany, March 06, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company...
Affimed Provides Clinical Response Update on AFM24-102 Trial in EGFR-wildtype Non-Small Cell Lung Cancer
Affimed Provides Clinical Response Update on AFM24-102 Trial in EGFR-wildtype Non-Small Cell Lung Cancer
Data update from AFM24-102 Phase 1/2a combination study includes 15 heavily pre-treated patients from the EGFR-wildtype (wt) non-small cell lung cancer...
Affimed CEO Adi Hoess to step down, Andreas Harstrick appointed interim CEO (NASDAQ:AFMD)
Affimed also said it will reduce its workforce by up to 50%.
Affimed Announces Leadership Change and Organizational Restructuring
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
It's time to dive into the biggest pre-market stock movers with all of the latest coverage worth reading about on Wednesday morning!
Affimed sells AbCheck unit for $6M (NASDAQ:AFMD)
Affimed (AFMD) has announced the sale of its subsidiary, AbCheck, to Ampersand Biomedicines for $6M. The deal includes cash, stock, and milestone payments.
Affimed Announces Sale of Wholly-Owned Subsidiary AbCheck
Affimed Announces Sale of Wholly-Owned Subsidiary AbCheck
MANNHEIM, Germany, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company...
3 Penny Stocks That Are Too Compelling to Ignore
Although the sector presents extraordinary risks, for those seeking extreme returns, these top penny stocks to buy could get it done.
Affimed erases gains despite positive trial data (NASDAQ:AFMD)
Affimed (AFMD) shares drop despite positive trial data for its innate cell engagers in patients with Hodgkin lymphoma and solid tumors with EGFR-expressing,...
Affimed Announces Positive Data for AFM24 in Combination with the PD-L1 Checkpoint Inhibitor Atezolizumab in Heavily Pre-treated EGFR-Wildtype Non-Small Cell Lung Cancer Patients
Data update from AFM24-102 Phase 1/2a combination study includes 15 heavily pre-treated patients from the EGFR-wildtype non-small cell lung cancer (NSCLC)...
Affimed Announces Updated Phase 1/2 Data from Acimtamig in Combination with Allogeneic NK in Hodgkin Lymphoma Patients Who Failed Prior Chemotherapy and Are Double-Refractory to Brentuximab Vedotin (BV) and Checkpoint Inhibitors (CPIs)
In 32 patients with relapsed/refractory (r/r) Hodgkin lymphoma (HL) treated at the recommended phase 2 dose level (RP2D), the objective response rate (ORR)...
Affimed to Host Investor Conference Call Highlighting Clinical Data for Acimtamig (AFM13) and AFM24
Affimed to Host Investor Conference Call Highlighting Clinical Data for Acimtamig (AFM13) and AFM24
Review clinical data of acimtamig in combination with cord-blood derived NK cells presented at ASH 2023; provide progress update on the LuminICE-203Review...
Affimed Reports Third Quarter 2023 Financial Results and Highlights Operational Progress
Affimed Reports Third Quarter 2023 Financial Results and Highlights Operational Progress
Acimtamig (also known as AFM13) combination with AlloNK® (also known as AB-101): Initiated LuminICE-203. Company on track to report initial data in H1...
Affimed Announces Acimtamig as International Nonproprietary Name for AFM13
Affimed Announces Acimtamig as International Nonproprietary Name for AFM13
MANNHEIM, Germany, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company...